Top

Open Access 12-04-2025 | Clopidogrel | ORIGINAL RESEARCH

CILO-CLOP Trial: Cilostazol Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke: A Randomized Controlled Multicenter Trial

Authors: Mohamed G. Zeinhom, Mohamed Ismaiel, Mohamed Fouad Elsayed Khalil, Mohamed Ahmed Almoataz, Tarek Youssif Omar, Ahmed Mohamed Ali Daabis, Hossam Mohamed Refat, Ahmed Ahmed Mohamed Kamal Ebied, Noha Abdelwahed, Ahmed Zaki Omar Akl, Emad Labib Abdelhamid Mahmoud, Salah Ibrahim Ahmed, Sherihan Rezk Ahmed

Published in: Neurology and Therapy

Abstract

Introduction

All large studies evaluating the role of cilostazol versus other antiplatelet agents in stroke prevention have been conducted in Asia and included patients with minor stroke or transient ischemic attack (TIA). Ours is the first-ever trial to evaluate the safety and efficacy of cilostazol versus clopidogrel in moderate and moderate-to-severe ischemic stroke in North Africa. Accordingly, in this study we assess the role of cilostazol as an alternative to clopidogrel in Egyptian patients with first-ever non-cardioembolic moderate or moderate-to-severe ischemic stroke.

Methods

A total of 870 patients with moderate and moderate-to-severe acute ischemic stroke (AIS) were randomly assigned to administration of loading and maintenance doses of cilostazol or clopidogrel.

Results

Of the 870 patients included in our trial, 37 (8.7%) in the cilostazol arm and 59 (13.6%) in the clopidogrel arm experienced a new stroke (HR 0.53; 95% CI, 0.33–0.84; P = 0.007). Twelve participants (2.8%) in the cilostazol group and 25 patients (5.7%) in the clopidogrel group experienced drug-related hemorrhagic complications (HR 0.25; 95% CI, 0.12–0.53; P = 0.001). Patients with hypertension who received cilostazol had significantly lower rates of recurrent hemorrhagic and ischemic stroke.

Conclusion

Egyptian patients with non-cardioembolic moderate and moderate-to-severe ischemic stroke who received cilostazol within the first 24 h of symptoms had significantly lower rates of hemorrhagic transformation of brain infarction and peripheral hemorrhagic complications than those who received clopidogrel. Patients with hypertension achieved the greatest benefit from cilostazol, as they experienced a significant reduction in recurrent ischemic and hemorrhagic infarction. There were no significant differences between the two groups regarding the modified Rankin scale (mRS) score after 3 months or in the non-hemorrhagic side effects. Our results were derived from a single-blinded study; a more extensive, double-blinded, multinational study is needed for the results to be generalizable worldwide.

Trial Registration: Retrospectively registered, ClinicalTrials.gov, NCT06242132, 27-01-2024.

Zeinhom MG, Elbassiouny A, Mahmoud A, Sherihan M, Ahmed R. Ticagrelor versus clopidogrel in acute large-vessel ischemic stroke: a randomized controlled single-blinded trial. CNS Drugs. 2024;38(5):387–93. https://doi.org/10.1007/s40263-024-01080-5.CrossRefPubMedPubMedCentral

Aref HM, El-Khawas H, Elbassiouny A, Shokri HM, Zeinhom MG, Roushdy TM. A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. Neurol Sci. 2023;44(2):765–71. https://doi.org/10.1007/s10072-022-06525-7.CrossRefPubMed

Powers WJ, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke. Stroke. 2019;50(12):e344–418. https://doi.org/10.1161/STR.0000000000000211.CrossRefPubMed

Zeinhom MG, et al. Predictors of the unfavorable outcomes in acute ischemic stroke patients treated with alteplase, a multi-center randomized trial. Sci Rep. 2024;14(1):1–9. https://doi.org/10.1038/s41598-024-56067-5.CrossRef

Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischemic strokes compared. Stroke. 2009;40(6):2068–72. https://doi.org/10.1161/STROKEAHA.108.540112.CrossRefPubMed

Tani T, Sakurai K, Kimura Y, Ishikawa T, Hidaka H. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. Adv Second Messenger Phosphoprotein Res. 1992;25:215–27.PubMed

Rondina MT, Weyrich AS. Targeting phosphodiesterases in anti-platelet therapy. Handb Exp Pharmacol. 2012;210:225–38. https://doi.org/10.1007/978-3-642-29423-5_9.CrossRef

Volney C, Collins A, Adams S. Ticagrelor versus clopidogrel in the management of acute myocardial infarction. J Commun Hosp Intern Med Perspect. 2019;9(4):314–8. https://doi.org/10.1080/20009666.2019.1644915.CrossRef

Winter MP, Koziński M, Kubica J, Aradi D, Siller-Matula JM. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postep w Kardiol Interwencyjnej. 2015;11(4):259–80. https://doi.org/10.5114/pwki.2015.55596.CrossRef

10.

McHutchison C, et al. Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis. Stroke. 2020;51(8):2374–85. https://doi.org/10.1161/STROKEAHA.120.029454.CrossRefPubMedPubMedCentral

11.

Zeinhom MG, et al. A multicenter trial on the predictors of different subtypes of hemorrhagic infarction after thrombolysis. Sci Rep. 2024;14(1):29822. https://doi.org/10.1038/s41598-024-76189-0.CrossRefPubMedPubMedCentral

12.

Julie Fussner CV. Assessing stroke—scores & scales. Am. Stroke Assoc., pp. 1–23; 2019. https://www.heart.org/-/media/files/affiliates/gra/gra-qsi/2019-scbc-presentations/5-assessing-stroke-scores-scales-v2.pdf?la=en

13.

Kogan E, Twyman K, Heap J, Milentijevic D, Lin JH, Alberts M. Assessing stroke severity using electronic health record data: a machine learning approach. BMC Med Inform Decis Mak. 2020;20(1):8. https://doi.org/10.1186/s12911-019-1010-x.CrossRefPubMedPubMedCentral

14.

Zeinhom MG, Aref HM, El-Khawas H, Roushdy TM, Shokri HM, Elbassiouny A. A pilot study of the ticagrelor role in ischemic stroke secondary prevention. Eur Neurol. 2022;85(1):50–5. https://doi.org/10.1159/000518786.CrossRefPubMed

15.

Matsuoka S, et al. Age modified relationship between modifiable risk factors and the risk of atrial fibrillation. Circ Arrhythmia Electrophysiol. 2022;15(1): e010409. https://doi.org/10.1161/CIRCEP.121.010409.CrossRef

16.

Mentz RJ, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329(3):214–23. https://doi.org/10.1001/jama.2022.23924.CrossRefPubMedPubMedCentral

17.

Zeller T, Trenk D. Cilostazol. Circulation. 2013;127(23):2261–3. https://doi.org/10.1161/CIRCULATIONAHA.113.003284.CrossRefPubMed

18.

Hart RG, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–38. https://doi.org/10.1016/S1474-4422(13)70310-7.CrossRefPubMed

19.

Ntaios G, Hart RG. Embolic stroke. Circulation. 2017;136(25):2403–5. https://doi.org/10.1161/CIRCULATIONAHA.117.030509.CrossRefPubMed

20.

Hindricks G, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.CrossRefPubMed

21.

De Havenon A, et al. Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities. Stroke. 2021;52(10):E635–45. https://doi.org/10.1161/STROKEAHA.121.035002.CrossRefPubMedPubMedCentral

22.

Bates ER, Lau WC, Angiolillo DJ. Clopidogrel–drug interactions. J Am Coll Cardiol. 2011;57(11):1251–63. https://doi.org/10.1016/j.jacc.2010.11.024.CrossRefPubMed

23.

Weimar C, et al. Assessment of functioning and disability after ischemic stroke. Stroke. 2002;33(8):2053–9. https://doi.org/10.1161/01.str.0000022808.21776.bf.CrossRefPubMed

24.

Rezk S, Nevine A, Nahas E, Fouad M, Khalil E, Elbassiouny A. TICA-CLOP STUDY: ticagrelor versus clopidogrel in acute moderate and moderate-to-severe ischemic stroke, a randomized controlled multi-center trial. CNS Drugs. 2024;39(1):81–93. https://doi.org/10.1007/s40263-024-01127-7.CrossRef

25.

De Marchis GM, et al. New avenues for optimal treatment of atrial fibrillation and stroke prevention. Stroke. 2021;52(4):1490–9. https://doi.org/10.1161/STROKEAHA.120.032060.CrossRefPubMed

26.

Elgamal S, Ahmed SR, Nahas MM, Hendawy SR, Elshafei O, Zeinhom MG. The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial. Acta Neurol Belg. 2024;124(3):965–72. https://doi.org/10.1007/s13760-024-02499-9.CrossRefPubMedPubMedCentral

27.

Unger T, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–57. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026.CrossRefPubMed

28.

Liu L, et al. Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology. 2015;85(13):1154–62.CrossRefPubMedPubMedCentral

29.

Park TH, et al. Neurologic deterioration in patients with acute ischemic stroke or transient ischemic attack. Neurology. 2020. https://doi.org/10.1212/WNL.0000000000010603.CrossRefPubMedPubMedCentral

30.

Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202–4. https://doi.org/10.1111/j.1538-7836.2009.03678.x.CrossRefPubMed

31.

Furlan AJ. Acute stroke trials: strengthening the underpowered. Stroke. 2002;33(6):1450–1. https://doi.org/10.1161/01.STR.0000018645.04200.7D.CrossRefPubMed

32.

Wang C, et al. Ticagrelor versus clopidogrel in minor stroke or transient ischemic attack with intracranial artery stenosis: a post hoc analysis of CHANCE-2. J Am Heart Assoc. 2023;12(21):1–12. https://doi.org/10.1161/JAHA.123.031611.CrossRef

33.

Köhrmann M, Schellinger PD. Symptomatic intracranial hemorrhage after thrombolysis. Cerebrovasc Dis (Basel, Switzerland). 2007;23(2–3):83–4. https://doi.org/10.1159/000097042.CrossRef

34.

Chimowitz MI, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993–1003. https://doi.org/10.1056/NEJMoa1105335.CrossRefPubMedPubMedCentral

35.

Gotoh F, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2000;9(4):147–57. https://doi.org/10.1053/jscd.2000.7216.CrossRef

36.

Umekawa H, Tanaka T, Kimura Y, Hidaka H. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography. Biochem Pharmacol. 1984;33(21):3339–44. https://doi.org/10.1016/0006-2952(84)90103-5.CrossRefPubMed

37.

Minami N, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997;61(25):383–9. https://doi.org/10.1016/s0024-3205(97)00986-7.CrossRef

38.

Igawa T, et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res. 1990;57(4):617–23. https://doi.org/10.1016/0049-3848(90)90079-r.CrossRefPubMed

39.

Kim JS, Kwon SU, Uchiyama S. Cilostazol research in Asia: can it be applied to European and American patients? Int J Stroke Off J Int Stroke Soc. 2015;10(Suppl 1):1–9. https://doi.org/10.1111/ijs.12460.CrossRef

40.

Powers WJ, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018. https://doi.org/10.1161/STR.0000000000000158.CrossRefPubMed

41.

Chenna V, et al. Predictors of intracerebral hemorrhage in acute stroke patients receiving intravenous recombinant tissue plasminogen activator. Ann Indian Acad Neurol. 2018;21(3):214–9. https://doi.org/10.4103/aian.AIAN_228_17.CrossRefPubMedPubMedCentral

42.

Dorňák T, et al. Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of hemorrhage after thrombolysis. Int J Stroke. 2015;10(8):1224–8. https://doi.org/10.1111/ijs.12626.CrossRefPubMed

43.

Sun F, et al. Predictive factors of hemorrhage after thrombolysis in patients with acute ischemic stroke. Front Neurol. 2020;11(November):1–6. https://doi.org/10.3389/fneur.2020.551157.CrossRef

44.

Xue Y, et al. Predictors for symptomatic intracranial hemorrhage after intravenous thrombolysis with acute ischemic stroke within 6 h in northern China: a multicenter, retrospective study. BMC Neurol. 2022;22(1):1–7. https://doi.org/10.1186/s12883-021-02534-9.CrossRef

45.

Aoki J, et al. NIHSS-time score easily predicts outcomes in rt-PA patients: the SAMURAI rt-PA registry. J Neurol Sci. 2013;327(1–2):6–11. https://doi.org/10.1016/j.jns.2013.01.029.CrossRefPubMed

46.

Elsayed MA, Salah H, Sabbah A, Hatem G, Moawad MK. Early functional outcome after IV rTPA administration in Egyptian acute ischemic stroke patients. Egypt J Neurol Psychiatry Neurosurg. 2019. https://doi.org/10.1186/s41983-019-0110-y.CrossRef

47.

Johnston SC, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35–43. https://doi.org/10.1056/nejmoa1603060.CrossRefPubMed

48.

Wang Y, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385(27):2520–30. https://doi.org/10.1056/nejmoa2111749.CrossRefPubMed

49.

Dehbozorgi M, et al. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (-806 C>T) alleles among an Iranian population of different ethnicities. Mol Med Rep. 2018;17(3):4195–202. https://doi.org/10.3892/mmr.2018.8377.CrossRefPubMedPubMedCentral

50.

Messaoudi M, Pakstis AJ, Boussetta S, Ben Ammar Elgaaied A, Kidd KK, Cherni L. CYP2C gene polymorphisms in North African populations. Mol Biol Rep. 2024;51(1):1145. https://doi.org/10.1007/s11033-024-10093-8.CrossRefPubMed

51.

Liu L, et al. Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology. 2015;85(13):1154–62. https://doi.org/10.1212/WNL.0000000000001972.CrossRefPubMedPubMedCentral

52.

Liu H, et al. Comparison of cilostazol versus clopidogrel in addition to aspirin in patients with ischemic stroke who underwent intracranial or extracranial artery stent implantation. J Atheroscler Thromb. 2023;30(8):1010–21. https://doi.org/10.5551/jat.63632.CrossRefPubMed

53.

Kwon SU, et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke. 2011;42(10):2883–90. https://doi.org/10.1161/STROKEAHA.110.609370.CrossRefPubMed

54.

Lee TH, Lin YS, Liou CW, Der Lee J, Peng TI, Liu CH. Comparison of long-term efficacy and safety between cilostazol and clopidogrel in chronic ischemic stroke: a nationwide cohort study. Ther Adv Chronic Dis. 2020;11:1–14. https://doi.org/10.1177/2040622320936418.CrossRef

55.

Lee YJ, Je NK. Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. Eur J Clin Pharmacol. 2023;79(8):1107–16. https://doi.org/10.1007/s00228-023-03522-3.CrossRefPubMed

56.

Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6(4):3–11. https://doi.org/10.1016/j.atherosclerosissup.2005.09.002.CrossRefPubMed

57.

Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg. 2003;38(4):710–3. https://doi.org/10.1016/s0741-5214(03)01029-2.CrossRefPubMed

58.

Tamai Y, Takami H, Nakahata R, Ono F, Munakata A. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis. 1999;29(5):269–76. https://doi.org/10.1159/000022512.CrossRefPubMed

59.

de Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol. 2000;110(1):125–9. https://doi.org/10.1046/j.1365-2141.2000.02039.x.CrossRefPubMed

60.

Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31(4):817–21. https://doi.org/10.1161/01.str.31.4.817.CrossRefPubMed

61.

Fuster V, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee. J Am Coll Cardiol. 2001;38(4):1231–66. https://doi.org/10.1016/s0735-1097(01)01587-x.CrossRefPubMed

62.

Shi M-Q, et al. Cilostazol suppresses angiotensin II-induced apoptosis in endothelial cells. Mol Med Rep. 2016;13(3):2597–605. https://doi.org/10.3892/mmr.2016.4881.CrossRefPubMedPubMedCentral

63.

Johnston SC, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207–17. https://doi.org/10.1056/nejmoa1916870.CrossRefPubMed

64.

Johnston SC, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215–25. https://doi.org/10.1056/nejmoa1800410.CrossRefPubMedPubMedCentral

Title: CILO-CLOP Trial: Cilostazol Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke: A Randomized Controlled Multicenter Trial
Authors: Mohamed G. Zeinhom
Mohamed Ismaiel
Mohamed Fouad Elsayed Khalil
Mohamed Ahmed Almoataz
Tarek Youssif Omar
Ahmed Mohamed Ali Daabis
Hossam Mohamed Refat
Ahmed Ahmed Mohamed Kamal Ebied
Noha Abdelwahed
Ahmed Zaki Omar Akl
Emad Labib Abdelhamid Mahmoud
Salah Ibrahim Ahmed
Sherihan Rezk Ahmed
Publication date: 12-04-2025
Publisher: Springer Healthcare
Keywords: Clopidogrel
Transient Ischemic Attack
Published in: Neurology and Therapy
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI: https://doi.org/10.1007/s40120-025-00739-5

How can you integrate PET into your practice? (Link opens in a new window)

Alzheimer Disease
Independent Medical Education

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:

Lilly

Developed by: Springer Healthcare IME

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now